Gravel Biotechnology and Quangang Pharmaceutical Establish Strategic Partnership to Co-Develop TIL Cell Therapy Combined with Interleukin-2 (I) for Solid Tumor Treatment
Grit Biotherapeutics
Developer of Immunotherapy Drugs for Solid Tumors
Recently, Shanghai Grail Bio Co., Ltd. ("Grail Bio") and Shandong Quangang Pharmaceutical Co., Ltd. ("Quangang Pharmaceutical") announced the official establishment of a strategic partnership to fully leverage their respective capabilities in the research and development of innovative cell-based drugs.Aiming to jointly develop TIL cell therapy technology combined with recombinant human interleukin-2 (I) (trade name: Quanqi) for the treatment of solid tumors., to support the development and subsequent clinical use of T-cell therapy.
The signing of the agreement,Marks the strong alliance between the two parties in the biotechnology field, which will bring more effective and accessible treatment options to patients with solid tumors.It is reported that the focus of cooperative development will be on the expansion of solid tumor indications for Quanchi products.
Quanqi, as a domestically marketed Interleukin-2 (I) product in China, is mainly used for the treatment of malignant tumors such as renal cell carcinoma, melanoma, breast cancer, bladder cancer, liver cancer, rectal cancer, lymphoma, and lung cancer. It is an important immune-modulating cytokine in T-cell therapy, and its efficacy and safety play a crucial role in the effectiveness of cellular therapy.
This cooperation,Both parties will jointly commit to developing the clinical efficacy of TIL cell therapy combined with Quangang's treatment for solid tumors and developing a suitable specification of human interleukin-2 (I) for TIL cell therapy.Providing more solid support for T-cell therapy to meet the needs of Chinese patients with solid tumors for high-quality and highly efficient treatment.。
Grail Bio's TIL Cell Therapy Technology is an innovative immunotherapy technique that utilizes patients' own tumor-infiltrating lymphocytes (TIL) for treatment, offering a novel therapeutic option for patients with solid tumors.
Shandong Quangang Pharmaceutical Co., Ltd., a leading Chinese biopharmaceutical company specializing in the research, production, and sales of biologics, has rich technical expertise and experience in the development of recombinant protein drugs, enjoying a strong reputation and influence in the biopharmaceutical industry.
Through the cooperation with Shandong Quangang Pharmaceutical Co., Ltd., Grit Bio will leverage its experience in cell therapy product development and industrialization to accelerate the progress and market launch of cell therapy products, bringing new options and hope to more patients with solid tumors.
Both parties expressed that the establishment of this strategic partnership,This not only marks a solid step forward in the collaboration between Grail Bio and Shandong Quangang Pharmaceutical Co., Ltd. in the biopharmaceutical field but will also further accelerate the research and development process of TIL cell therapy combined with human interleukin-2 (IL-2) for the treatment of solid tumors, making a positive contribution to the advancement of China's cell therapy industry.We believe that, with the joint efforts of both parties, in the near future, Chinese patients with solid tumors will be able to access more advanced and effective biotherapy options, bringing new hope for the treatment of serious diseases such as cancer.
Source: Grail Bio
